The 11th Neurodegenerative Drug Development Summit is dedicated to argeting neurodegenerative diseases and challenging traditional thinking around disease aetiology.
Topics
- Shortcomings in preclinical models to confidently translate into clinical development
- Biological understanding of neurodegeneration and awareness of emerging targets for more promising target identification and selection
- Digital developments for their successful integration into clinical settings for earlier diagnosis
- Neurodegenerative biomarker advances that will improve scale sensitivity and clinical practicality for monitoring disease progression
- Pharmaceutical investment strategies and business models to financially de- risk neurodegenerative drug development
- Clinical trial design for homogeneous, rapidly progressing patient populations allowing for shorter, less expensive trials with more immediate benefit to patients and attractiveness to payers
- Genetic profiling of patients to manage clinical heterogeneity for patient stratification
Who should Attend
Consortia, leading scientists and pharmaceutical business leaders.
